Answers are grounded in this paper and cite their sources.
Fluconazole resistance in Candida parapsilosis is increasingly reported, but temporal trends from multicenter surveillance can be distorted by changes in the contributing population and by correlation among isolates from the same country. We analyzed 14,393 bloodstream Candida isolates from 44 countries in the SENTRY Antifungal Surveillance Program (Vivli AMR Register), 2010–2024; resistance analyses included 12,868 isolates of four species with CLSI breakpoints. The main analysis was the C. parapsilosis trend, estimated with a multivariable generalized estimating equation (GEE) clustered by country; the other species were secondary. C. parapsilosis resistance increased from 3.4% (2010–2014) to 14.7% (2020–2024); the adjusted GEE odds ratio per 5 years was 2.20 (95% CI 1.56–3.09). The point estimate suggested that measured country, demographic and clinical composition accounted for 1.8 of the 11.4 percentage-point increase (16%; bootstrap 95% CI −1.0 to 3.3, compatible with no contribution). The increase was greatest in Europe (3.2% to 26.9%) with a smaller descriptive increase in North America (2.7% to 7.8%); evidence for regional heterogeneity varied across models. Resistance declined in C. glabrata (9.5% to 4.5%; adjusted GEE OR 0.78, 95% CI 0.69–0.89) and remained rare in C. albicans. In this sentinel network, the increase in C. parapsilosis resistance persisted after addressing measured composition and country-level correlation, but it was concentrated in specific regions and should not be read as a uniform population-based global trend.
No takes yet. Share an insight, caveat, or question.
López et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: